




# PHARMACEUTICAL 2020

Esperion Therapeutics Inc.  
Rank 266 of 358

ESPERION





# PHARMACEUTICAL 2020

Esperion Therapeutics Inc.  
Rank 266 of 358

ESPERION

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -31%, being 67% points below the market average of 36%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 211,714           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 66,080            |
| Liabilities, Non-Current                    | 1,109             |
| Other Assets                                | 1,588             |
| Other Compr. Net Income                     | 342               |
| Other Expenses                              | 8,120             |
| Other Liabilities                           | 127,308           |
| Other Net Income                            | 4,056             |
| Other Revenues                              | 148,364           |
| Property and Equipment                      | 1,145             |
| Research and Development                    | 175,611           |
| Selling, General and Administrative Expense | 65,854            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 214,447           |
| Liabilities              | 194,497           |
| Expenses                 | 249,585           |
| Revenues                 | 148,364           |
| Stockholders Equity      | 19,950            |
| Net Income               | -97,165           |
| Comprehensive Net Income | -96,994           |
| Economic Capital Ratio   | -31%              |